EKR Therapeutics has received approval from the FDA for Cardene I.V. premixed injection, a patented, ready-to-use, single use intravenous bag for the administration of this calcium channel blocker.
The Cardene I.V. 200ml ready-to-use (RTU) bags contain 20mg of the anti-hypertensive agent nicardipine hydrochloride (0.1mg/ml) in either dextrose or sodium chloride.
EKR further noted that it will start taking orders immediately for the new RTU bags of Cardene. The RTU formulations are expected to expand the Cardene franchise which has primarily consisted of sales of ampoules of Cardene I.V.
Howard Weisman, chairman and CEO of EKR Therapeutics, said: “With the addition of the ready-to-use bags, the breadth of our Cardene product offerings has expanded greatly and we foresee opportunities for wider utilization of this anti-hypertensive across a range of acute-care settings.”
Comments